Results 1 to 10 of about 670,258 (300)
The Lancet, 2020 Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk factors for developing pancreatic cancer include family history, obesity, type 2 diabetes, and tobacco use.
Jonathan D, Mizrahi +3 more
openaire +4 more sources
EBioMedicine, 2022 Summary: Background: Previously, we uncovered a patient subgroup with highly malignant pancreatic cancer with serum markers CEA+/CA125+/CA19-9 ≥ 1000 U/mL (triple-positive, TP).
Longyun Ye +14 more
doaj +1 more source
Journal of Hematology & Oncology, 2022 Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of ...
Xuhui Tong +8 more
doaj +1 more source
Oncogenesis, 2022 Pancreatic ductal adenocarcinoma (PDAC) is a well-known lethal and heterogeneous disease. Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) is an important mutagenic driver that has seldom been investigated in PDAC. Therefore, this
Yunzhen Qian +13 more
doaj +1 more source
CA: A Cancer Journal for Clinicians, 1981 As a result of increased funding in the past few years, carcinoma of the pancreas has received increased investigative attention. A substantial body of epidemiologic data has been recorded, which may ultimately provide leads that identify an "at risk" population.
R M, Beazley, I, Cohn
openaire +2 more sources
World Journal of Surgical Oncology, 2021 Background Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC).
Yitao Gong +11 more
doaj +1 more source
World Journal of Surgical Oncology, 2022 Background Intraductal papillary mucinous neoplasms (IPMNs) are characterized by their abundant mucin production and malignant potential. IPMNs of the pancreas are mainly managed according to their radiographic indications, but this approach lacks ...
Yunzhen Qian +12 more
doaj +1 more source
CA: A Cancer Journal for Clinicians, 1994 Pancreatic cancer is a devastating disease for the patient and presents challenging diagnostic and management problems for the physician. A range of serologic and radiologic studies are available for evaluation and staging of this disease. However, invasive studies, including laparotomy, are often necessary to establish the diagnosis and resectability.
M M, Murr +3 more
openaire +2 more sources
BMJ, 2014 In recent years, it has become clear that the current standard therapeutic options for pancreatic cancer are not adequate and still do not meet the criteria to cure patients suffering from this lethal disease. Although research over the past decade has shown very interesting and promising new therapeutic options for these patients, only minor clinical ...
Ajith K, Siriwardena +1 more
openaire +4 more sources
The Lancet, 2016 Pancreatic cancer is a highly lethal disease, for which mortality closely parallels incidence. Most patients with pancreatic cancer remain asymptomatic until the disease reaches an advanced stage. There is no standard programme for screening patients at high risk of pancreatic cancer (eg, those with a family history of pancreatic cancer and chronic ...
Terumi, Kamisawa +3 more
+10 more sources